{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:52:16Z","timestamp":1787017936455,"version":"build-2736575974"},"reference-count":29,"publisher":"S. Karger AG","issue":"1","license":[{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,11,15]],"date-time":"2021-11-15T00:00:00Z","timestamp":1636934400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ocul Oncol Pathol"],"published-print":{"date-parts":[[2022]]},"abstract":"<b><i>Introduction:<\/i><\/b> Loss of BAP1 protein expression emerged as a negative prognostic marker in uveal melanoma (UM) and has primarily been studied in enucleations. Intraocular biopsy is frequently performed prior to UM globe-conserving therapy. <b><i>Methods:<\/i><\/b> We retrospectively evaluated BAP1 immunostaining of UM in 16 biopsies and 8 subsequent enucleations, and results were correlated with the UM-specific gene expression profile (GEP; <i>n<\/i> = 11), chromosome 3 status by FISH and\/or chromosomal microarray (<i>n<\/i> = 12; 9 also had GEP), and clinical outcomes. <b><i>Results:<\/i><\/b> UM involved the choroid in 15 (of 16) cases. Biopsy was performed for prognostication (<i>n<\/i> = 12) or diagnosis (<i>n<\/i> = 4). Treatment included brachytherapy (<i>n<\/i> = 13; 5 followed by enucleation) or enucleation only (<i>n<\/i> = 3). BAP1 nuclear immunostaining was positive in 9, negative in 4, and equivocal in 3 biopsies. For the 3 equivocal biopsies, BAP1 immunostaining was positive in 2 (of 3) subsequent enucleations. BAP1 immunostaining was concordant between all 5 remaining biopsies and enucleations. BAP1-positive biopsies had disomy 3 (<i>n<\/i> = 6) or 3p loss (<i>n<\/i> = 1) and class 1 GEP (<i>n<\/i> = 6). BAP1-negative biopsies had monosomy 3 (<i>n<\/i> = 3) and class 2 GEP (<i>n<\/i> = 2). Median follow-up was 62.5 months (range, 17\u2013150). For BAP1-positive UM patients, 8 were alive (7 without metastatic disease) and 3 had died (1 melanoma-related death). Among BAP1-negative UM patients, 2 were alive (1 with metastatic disease) and 3 had melanoma-related deaths. <b><i>Conclusion:<\/i><\/b> BAP1 immunostaining in biopsies highly correlates with results in subsequent enucleations and with well-established UM prognostic markers, representing a potential additional prognostic tool for UM biopsies.<\/jats:p>","DOI":"10.1159\/000515858","type":"journal-article","created":{"date-parts":[[2022,2,8]],"date-time":"2022-02-08T05:06:30Z","timestamp":1644296790000},"page":"22-29","source":"Crossref","is-referenced-by-count":7,"title":["BAP1 Immunostain Status in Intraocular Biopsy Specimens for Uveal Melanoma Highly Correlates with Other Prognostic Markers"],"prefix":"10.1159","volume":"8","author":[{"given":"Cristiane M.","family":"Ida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia T.","family":"Greipp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquin J.","family":"Garcia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy W.","family":"Olsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Dalvin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diva Regina","family":"Salom\u00e3o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,11,15]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-019-0440-9"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.06.012"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1126\/science.1194472"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.02.017"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1371\/currents.eogt.af8ba80fc776c8f1ce8f5dc485d4a618"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2016.09.008"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.07.003"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-020-0158-0"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2016.0913"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.16-20212"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/PAT.0000000000000002"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2014.417"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2014.43"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000645"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2018.03.005"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.22541"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-16276-8"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-15606-0"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-013-2515-0"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2015.11.005"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305047"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2017.07.018"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.8.3.11"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000502550"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-14256-1"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2019.5403"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12041039"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(98)00040-3"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.1790"}],"container-title":["Ocular Oncology and Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/515858","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/515858","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T12:38:57Z","timestamp":1745411937000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000515858"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,15]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,2,15]]},"published-print":{"date-parts":[[2022,3,8]]}},"URL":"https:\/\/doi.org\/10.1159\/000515858","archive":["Portico"],"relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.6084\/m9.figshare.17011553","asserted-by":"subject"}]},"ISSN":["2296-4681","2296-4657"],"issn-type":[{"value":"2296-4681","type":"print"},{"value":"2296-4657","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,15]]}}}